Article Text
Abstract
“Run-in” and “washout” periods involving the withholding of medication are widely used in drug research trials in pursuit of both patient safety and scientific reliability. Such no-medication periods can be justified ethically provided that they are apparent to patients, who can thereby properly consent to undergoing them. Less widespread, but still common, is the practice of “single blinding” no-medication periods, concealing them from patients by means of placebo. Whilst all placebos involve a measure of concealment, their use is typically justified in drug research trials (i) by their preserving the uncertainty generated by the random allocation of different treatments within a drug trial; and (ii) by the researchers openly declaring both the randomisation process and the chances of receiving placebo. In the single blind placebo “run-in” or “washout”, neither of these conditions is met.
This paper considers three possible defences of the practice of using single blind placebo “run-ins” or “washouts” and finds them all to fail; the practice appears ethically unjustified.
- Drug trials
- single blind placebos
- consent
- deception
- “run-ins”
- “washouts”
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Commentary: Placebo run ins have some value
- Design of treatment trials for functional gastrointestinal disorders
- Replication crisis and placebo studies: rebooting the bioethical debate
- More than consent for ethical open-label placebo research
- Patient attitudes about the clinical use of placebo: qualitative perspectives from a telephone survey
- Are placebo run ins justified?
- Physician perspectives on placebo ethics
- The ethics of the placebo in clinical practice revisited
- The ethics of placebo treatments in clinical practice: a reply to Glackin
- Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet